Research

Mixed

Combined therapy with interferon-alfa and ribavirin for 48 weeks is effective and cost-effective for treating mild chronic hepatitis C in patients under 65, achieving sustained virological response (SVR) rates of 33% overall and 49% for non-genotype 1.

For adults with mild chronic hepatitis C, a 48-week course of interferon-alfa and ribavirin is a clinically effective and economically viable option, particularly for those under 65 and those with non-genotype 1 strains. While the treatment causes temporary side effects and a dip in quality of life, successful clearance of the virus (SVR) leads to long-term health benefits and improved quality of life, making it a superior choice to 'watchful waiting' for this demographic.

GoodSupportsHIGH confidence
In the treatment group, 32 out of 98 patients (33%) achieved an SVR. Patients infected with genotype 1 had a lower SVR than those infected with genotype non-1 (18% versus 49%, p = 0.02)... Based on the evidence collected in this study, interferon-alfa and ribavirin treatment for mild chronic hepatitis C patients is in general cost-effective at the £30,000 per QALY threshold previously used by policy-makers in the NHS.
Emma Loveman et al. · Health Technology Assessment · 2011

Why this rating

Multi-center, randomized, controlled trial with economic modeling.

Source

The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review

Emma Loveman et al. · Health Technology Assessment · 2011

DOI 10.3310/hta15020

rct · n=98Cited 299×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →